According to the CDC Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. In 2019 an estimated 229 million cases of malaria occurred worldwide and 409,000 people died, mostly children in the African Region. About 2,000 cases of malaria are diagnosed in the United States each year. The vast majority of cases in the United States are in travelers and immigrants returning from countries where malaria transmission occurs, many from sub-Saharan Africa and South Asia.
Mosquirix RTS,S/AS01 Malaria Vaccine - GSK's Mosquirix RTS, S/AS01 is a recombinant vaccine consisting of the P. falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage. Mosquirix aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host’s bloodstream through a mosquito bite and infects liver cells.
Malaria Vaccine Candidates
R21 / Matrix-M Malaria Vaccine - Serum Institute of India's R21 vaccine candidate is produced by expressing recombinant HBsAg virus-like particles in Hansenula polymorpha, comprising the central repeat and the C-terminus of the circumsporozoite protein (CSP) fused to the N-terminal end of HBsAg10.
RH5.1/AS01 Malaria Vaccine - RH5.1/AS01 is a novel, recombinant malaria antigen developed at the University of Oxford.
mRNA Malaria Vaccine - Announced July 26, 2021, BioNTech wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end of 2022, in an attempt to eradicate the mosquito-borne illness.